According to the systematic review conducted by Stacey et al. [17], the impacts of the three papers reporting on the statistically significant effects of PtDA as a decision-making tool for PSA testing as prostate cancer screening were 9% to 42% (Table 3) [29-31]. The gene discussed is KLK3; the disease is Familial prostate cancer.